Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3701_Библиотеки_им_академика_М_И_Перельмана
.pdf
Novel Pathogenesis and Treatments for Cardiovascular Disease
191
https://t.me/medicina_free
Cardiology Foundation and the
American Heart Association.
Circulation. 2009;119(2):351-357. DOI:
10.1161/CIRCULATIONAHA.108.
191305
[15] Castagno D, Baird-Gunning J, Jhund
PS, Biondi-Zoccai G, MacDonald MR,
Petrie MC, et al. Intensive glycemic
control has no impact on the risk of heart
failure in type 2 diabetic patients:
Evidence from a 37,229 patient metaanalysis. American Heart Journal. 2011;
162:938-948.e2. DOI: 10.1016/j.
ahj.2011.07.030
[16] Shindler DM et al. Diabetes mellitus,
a predictor of morbidity and mortality in
the studies of left ventricular
dysfunction (SOLVD) trials and registry.
The American Journal of Cardiology.
1996;77(11):1017-1020. DOI: 10.1016/
s0002-9149(97)89163-1
[17] Dries DL et al. Prognostic impact of
diabetes mellitus in patients with heart
failure according to the etiology of left
ventricular systolic dysfunction. Journal
of the American College of Cardiology.
2001;38(2):421-428. DOI: 10.1016/
s0735-1097(01)01408-5
[18] Gustafsson I et al. Influence of
diabetes and diabetes-gender interaction
on the risk of death in patients
hospitalized with congestive heart
failure. Journal of the American College
of Cardiology. 2004;43(5):771-777. DOI:
10.1016/j.jacc.2003.11.024
[19] Kristensen SL et al. Risk related to
pre-diabetes mellitus and diabetes
mellitus in heart failure with reduced
ejection fraction: Insights from
prospective comparison of ARNI with
ACEI to determine impact on global
mortality and morbidity in heart failure
trial. Circulation. Heart failure. 2016;9
(1):e002560. DOI: 10.1161/
CIRCHEARTFAILURE.115.002560
[20] Allen LA et al. Risk factors for
adverse outcomes by left ventricular
ejection fraction in a contemporary heart
failure population. Circulation. Heart
failure. 2013;6(4):635-646. DOI:
10.1161/CIRCHEARTFAILURE.
112.000180
[21] MacDonald MR et al. Impact of
diabetes on outcomes in patients with
low and preserved ejection fraction heart
failure: An analysis of the candesartan in
heart failure: Assessment of reduction in
mortality and morbidity (CHARM)
programme. European Heart Journal.
2008;29(11):1377-1385. DOI: 10.1093/
eurheartj/ehn153
[22] Kristensen SL et al. Clinical and
echocardiographic characteristics and
cardiovascular outcomes according to
Diabetes status in patients with heart
failure and preserved ejection fraction: A
report from the I-preserve trial
(Irbesartan in heart failure with
preserved ejection fraction). Circulation.
2017;135(8):724-735. DOI: 10.1161/
CIRCULATIONAHA.116.024593
[23] Hong J et al. Effects of metformin
versus glipizide on cardiovascular
outcomes in patients with type 2 diabetes
and coronary artery disease. Diabetes
Care. 2013;36(5):1304-1311. DOI:
10.2337/dc12-0719
[24] Kooy A et al. Long-term effects of
metformin on metabolism and
microvascular and macrovascular
disease in patients with type 2 diabetes
mellitus. Archives of Internal Medicine.
2009;169(6):616-625. DOI: 10.1001/
archinternmed.2009.20
[25] Maruthur NM et al. Diabetes
medications as monotherapy or
metformin-based combination therapy
for type 2 Diabetes: A systematic review
and meta-analysis. Annals of Internal
20
Diabetes
192
https://t.me/medicina_free
DOI:
Mellitus Type 2, Prediabetes, and Chronic Heart Failure
http://dx.doi.org/10.5772/.106391
Medicine. 2016;164(11):740-751. DOI:
10.7326/M15-2650
[26] Halabi A, Sen J, Huynh Q, et al.
Metformin treatment in heart failure
with preserved ejection fraction: A
systematic review and meta-regression
analysis. Cardiovascular Diabetology.
2020;19:124. DOI: 10.1186/s12933-02001100-w
[27] American Diabetes Association
Professional Practice Committee et al. 9.
Pharmacologic approaches to glycemic
treatment: Standards of medical care in
diabetes-2022. Diabetes Care. 2022;45
(Suppl 1):S125-S143. DOI: 10.2337/dc22S009
[28] Genuth S. Should sulfonylureas
remain an acceptable first-line add-on to
metformin therapy in patients with type
2 diabetes? No, it's time to move on!
Diabetes Care. 2015;38(1):170-175. DOI:
10.2337/dc14-0565
[29] Costello RA, Nicolas S, Shivkumar A.
Sulfonylureas. [Updated 2021 Aug 23].
In: StatPearls [Internet]. Treasure Island
(FL): StatPearls Publishing; 2022.
Available from: https://www.ncbi.nlm.
nih.gov/books/NBK513225/
[30] Krentz AJ, Bailey CJ. Oral
antidiabetic agents: Current role in type
2 diabetes mellitus. Drugs. 2005;65(3):
385-411. DOI: 10.2165/00003495200565030-00005
[31] Abdelmoneim AS et al. Variations in
tissue selectivity amongst insulin
secretagogues: A systematic review.
Diabetes, Obesity & Metabolism. 2012;
14(2):130-138. DOI: 10.1111/j.1463-
1326.2011.01496.x
[32] Bodmer M et al. Metformin,
sulfonylureas, or other antidiabetes
drugs and the risk of lactic acidosis or
hypoglycemia: A nested case-control
analysis. Diabetes Care. 2008;31(11):
2086-2091. DOI: 10.2337/dc08-1171
[33] Goto A et al. Severe hypoglycaemia
and cardiovascular disease: Systematic
review and meta-analysis with bias
analysis. BMJ (Clinical Research Ed.).
2013;347:f4533. DOI: 10.1136/bmj.f4533
[34] Mattishent K, Loke YK. Meta-
analysis: Association between
hypoglycemia and serious adverse events
in older patients treated with glucoselowering agents. Frontiers in
Endocrinology. 2021;12:571568. DOI:
10.3389/fendo.2021.571568
[35] Monami M et al. Cardiovascular
safety of sulfonylureas: A meta-analysis
of randomized clinical trials. Diabetes,
Obesity & Metabolism. 2013;15(10):938-
953. DOI: 10.1111/dom.12116
[36] Rosenstock J et al. Effect of
linagliptin vs glimepiride on major
adverse cardiovascular outcomes in
patients with type 2 diabetes: The
CAROLINA randomized clinical trial.
JAMA. 2019;322(12):1155-1166. DOI:
10.1001/jama.2019.13772
[37] Simpson SH et al. Mortality risk
among sulfonylureas: A systematic
review and network meta-analysis. The
Lancet. Diabetes & Endocrinology. 2015;
3(1):43-51. DOI: 10.1016/S2213-8587(14)
70213-X
[38] Douros A et al. Pharmacologic
differences of sulfonylureas and the risk
of adverse cardiovascular and
hypoglycemic events. Diabetes Care.
2017;40(11):1506-1513. DOI: 10.2337/
dc17-0595
[39] Bailey CJ. Thiazolidinediones,
Reference Module in Biomedical
Sciences. United Kingdom: Elsevier;
2015. DOI: 10.1016/B978-0-12-801238-
3.10867-0
21
Novel Pathogenesis and Treatments for Cardiovascular Disease
193
https://t.me/medicina_free
[40] Singh S et al. Thiazolidinediones and
heart failure: A teleo-analysis. Diabetes
Care. 2007;30(8):2148-2153. DOI:
10.2337/dc07-0141
[41] Lago RM et al. Congestive heart
failure and cardiovascular death in
patients with prediabetes and type 2
diabetes given thiazolidinediones: A
meta-analysis of randomised clinical
trials. Lancet (London, England). 2007;
370(9593):1129-1136. DOI: 10.1016/
S0140-6736(07)61514-1
[42] Wallach JD et al. Updating insights
into rosiglitazone and cardiovascular risk
through shared data: Individual patient
and summary level meta-analyses. BMJ
(Clinical Research Ed.). 2020;368:l7078.
DOI: 10.1136/bmj.l7078
[43] Brunton SA, Wysham CH. GLP-1
receptor agonists in the treatment of
type 2 diabetes: Role and clinical
experience to date. Postgraduate
Medicine. 2020;132(sup 2):3-14. DOI:
10.1080/00325481.2020.1798099
[44] Aroda VR. A review of GLP-1
receptor agonists: Evolution and
advancement, through the lens of
randomised controlled trials. Diabetes,
Obesity & Metabolism. 2018;20(Suppl
1):22-33. DOI: 10.1111/dom.13162
[45] Chatterjee S et al. What have we
learnt from "real world" data,
observational studies and meta-analyses.
Diabetes, Obesity & Metabolism. 2018;
20(Suppl 1):47-58. DOI: 10.1111/
dom.13178
[46] Levin PA et al. Glucagon-like
peptide-1 receptor agonists: A systematic
review of comparative effectiveness
research. Diabetes, Metabolic Syndrome
and Obesity: Targets and Therapy. 2017;
10:123-139. DOI: 10.2147/DMSO.
S130834
[47] Trujillo JM et al. GLP-1 receptor
agonists: An updated review of head-tohead clinical studies. Therapeutic
Advances in Endocrinology and
Metabolism. 2021;12:2042018821997320.
DOI: 10.1177/2042018821997320
[48] Andreadis P et al. Semaglutide for
type 2 diabetes mellitus: A systematic
review and meta-analysis. Diabetes,
Obesity & Metabolism. 2018;20(9):2255-
2263. DOI: 10.1111/dom.13361
[49] American Diabetes Association
Professional Practice Committee. 10.
Cardiovascular disease and risk
management: Standards of medical care
in diabetes—2022. Diabetes Care. 2022;
45(Supplement_1):S144-S174. DOI:
10.2337/dc22-S010
[50] Marso SP, Holst AG, Vilsbøll T.
Semaglutide and cardiovascular
outcomes in patients with type 2
diabetes. New England Journal of
Medicine. 2017;376:891-892. DOI:
10.1056/NEJMc1615712
[51] Demuth H-U et al. Type 2 diabetes—
Therapy with dipeptidyl peptidase IV
inhibitors. Biochimica et Biophysica
Acta. 2005;1751(1):33-44. DOI: 10.1016/
j.bbapap.2005.05.010
[52] Cahn A et al. An update on DPP-4
inhibitors in the management of type 2
diabetes. Expert Opinion on Emerging
Drugs. 2016; 21 (4):409-419. DOI:
10.1080/14728214.2016.1257608
[53] Scirica BM et al. Saxagliptin and
cardiovascular outcomes in patients with
type 2 diabetes mellitus. The New
England Journal of Medicine. 2013;369
(14):1317-1326. DOI: 10.1056/
NEJMoa1307684
[54] McMurray JJV et al. Effects of
vildagliptin on ventricular function in
patients with type 2 diabetes mellitus
22
Diabetes
194
https://t.me/medicina_free
DOI:
Mellitus Type 2, Prediabetes, and Chronic Heart Failure
http://dx.doi.org/10.5772/.106391
and heart failure: A randomized placebocontrolled trial. JACC. Heart Failure.
2018;6(1):8-17. DOI: 10.1016/j.
jchf.2017.08.004
[55] McDonagh TA et al. Corrigendum to:
2021 ESC Guidelines for the diagnosis
and treatment of acute and chronic heart
failure: Developed by the Task Force for
the diagnosis and treatment of acute and
chronic heart failure of the European
Society of Cardiology (ESC) With the
special contribution of the Heart Failure
Association (HFA) of the ESC. European
Heart Journal. 2021;42(48):4901. DOI:
10.1093/eurheartj/ehab670
[56] Hsia DS et al. An update on sodium-
glucose co-transporter-2 inhibitors for
the treatment of diabetes mellitus.
Current Opinion in Endocrinology,
Diabetes, and Obesity. 2017;24(1):73-79.
DOI: 10.1097/MED.0000000000000311
[57] Wiviott SD et al. Dapagliflozin and
cardiovascular outcomes in type 2
diabetes. The New England Journal of
Medicine. 2019;380(4):347-357. DOI:
10.1056/NEJMoa1812389
[58] Perkovic V et al. Canagliflozin and
renal outcomes in type 2 diabetes and
nephropathy. The New England Journal
of Medicine. 2019;380(24):2295-2306.
DOI: 10.1056/NEJMoa1811744
[59] Zinman B et al. Empagliflozin,
cardiovascular outcomes, and mortality
in type 2 diabetes. The New England
Journal of Medicine. 2015;373(22):2117-
2128. DOI: 10.1056/NEJMoa1504720
[60] Neal B et al. Canagliflozin and
cardiovascular and renal events in type 2
diabetes. The New England Journal of
Medicine. 2017;377(7):644-657. DOI:
10.1056/NEJMoa1611925
[61] Cannon CP et al. Cardiovascular
outcomes with Ertugliflozin in type 2
diabetes. The New England Journal of
Medicine. 2020;383(15):1425-1435. DOI:
10.1056/NEJMoa2004967
[62] Cosentino F et al. Efficacy of
Ertugliflozin on heart failure-related
events in patients with type 2 diabetes
mellitus and established atherosclerotic
cardiovascular disease: Results of the
VERTIS CV trial. Circulation. 2020;142
(23):2205-2215. DOI: 10.1161/
CIRCULATIONAHA.120.050255
[63] Snell-Bergeon JK, Wadwa RP.
Hypoglycemia, diabetes, and
cardiovascular disease. Diabetes
Technology & Therapeutics. 2012;14
(Suppl 1):S51-S58. DOI: 10.1089/
dia.2012.0031
[64] Shen L et al. Insulin treatment and
clinical outcomes in patients with
diabetes and heart failure with preserved
ejection fraction. European Journal of
Heart Failure. 2019;21(8):974-984. DOI:
10.1002/ejhf.1535
[65] Echouffo-Tcheugui JB et al. Severe
hypoglycemia and incident heart failure
among adults with type 2 diabetes. The
Journal of Clinical Endocrinology and
Metabolism. 2022;107(3):e955-e962.
DOI: 10.1210/clinem/dgab794
[66] Tuso P. Prediabetes and lifestyle
modification: Time to prevent a.
preventable disease. The Permanente
Journal. 2014;18(3):88-93. DOI: 10.7812/
TPP/14-002
[67] Centers for Disease Control and
Prevention. National Diabetes Statistic
Report. Available from: https://www.cdc
.gov/diabetes/data/statistics-report/inde
x.html [Accessed: 09 August 2022]
[68] Weatherspoon D, MacGill M. All
about borderline diabetes (prediabetes).
Medical News Today. 2019. Available
23
Novel Pathogenesis and Treatments for Cardiovascular Disease
195
https://t.me/medicina_free
from: https://www.medicalnewstoday.c
om/articles/311240
[69] Chakraborty M, Singh P, Dsouza J.
Fasting and postprandial lipid
parameters: A comparative evaluation of
cardiovascular risk assessment in
prediabetes and diabetes. Journal of
Family Medicine and Primary Care.
2020;9(1):287-292. DOI: 10.4103/jfmpc.
jfmpc_769_19
[70] Sörensen B et al. Prediabetes and
type 2 diabetes are associated with
generalized microvascular dysfunction.
Circulation. 2016;134:1339-1352
[71] Papanas N et al. Neuropathy in
prediabetes: Does the clock start ticking
early? Nature Reviews Endocrinology.
2011;7:682-690
[72] Vistisen D, Kivimäki M, Perreault L,
et al. Reversion from prediabetes to
normoglycaemia and risk of
cardiovascular disease and mortality:
The Whitehall II cohort study.
Diabetologia. 2019;62(8):1385-1390
[73] Classification of Diabetes Mellitus
2019, WHO 2019; 8. Available from: h
ttps://www.who.int/publications/i/item/
classification-of-diabetes-mellitus
[74] International Diabetes Federation.
Recommendations for Managing Type 2
Diabetes in Primary Care. 2017.
Available from: https://www.idf.org/
managing-type2-diabetes
[75] Diabetes Canada Clinical Practice
Guidelines Expert Committee et al.
Definition, classification and diagnosis
of diabetes, prediabetes and metabolic
syndrome. Canadian Journal of Diabetes.
2018;42(Suppl 1):s10-s15. DOI: 10.1016/
j.jcjd.2017.10.003
[76] Bell K, Shaw J, Brown L, et al. A
position statement on screening and
management of prediabetes in adults in
primary care in Australia. Diabetes
Research and Clinical Practice. 2020;
164:108-188
[77] Prediabetes diagnosis impaired
glucose tolerance. 2019. Available from:
http://diabetes.co.uk
[78] American Diabetes Association. 2.
Classification and diagnosis of diabetes:
Standards of Medical Care in Diabetes—
2022. Diabetes Care. 2022;45
(Supplement_1):S17-S38. DOI: 10.2337/
dc22-S002
[79] Mirzazade VA, Aliyeva TT,
Abbasova NE, Mammadhasanov RM, et
al. Standards of Diagnosis Diabetes
Mellitus and Prediabetes. Invitation to
Discussion. Baku: Azerbaijan Association
of Endocrinology, Diabetology and
Therapeutic Education “AzerDiab”; 2017
[80] Akter N, Qureshi NK. Comparison
of IDRS, ADA and FINDRISC diabetes
risk assessment tools: A cross-sectional
analysis in a tertiary care hospital. Sri
Lanka Journal of Diabetes Endocrinology
and Metabolism. 2020;10(2):10-20. DOI:
10.4038/sjdem.v10i2.7415
[81] Wong KC et al. Ausdrisk:
Application in General Practice.
Australian Family Physician. 2011;40:
524-526
[82] Schlesinger S, Neuenschwander M,
et al. Prediabetes and risk of mortality,
diabetes-related complications and
comorbidities: Umbrella review of metaanalyses of prospective studies.
Diabetologia. 2022;65(2):275-285. DOI:
10.1007/s00125-021-05592-3
[83] Sinha A, Ning H, Ahmad FS, et al.
Association of fasting glucose with
lifetime risk of incident heart failure: The
lifetime risk pooling project.
24
Diabetes
196
https://t.me/medicina_free
DOI:
Mellitus Type 2, Prediabetes, and Chronic Heart Failure
http://dx.doi.org/10.5772/.106391
Cardiovascular Diabetology. 2021;
20(1):66
[84] The association between glucose
abnormalities and heart failure in the
population-based Reykjavik study.
Available from: https://www.hirsla.lsh.
is/handle/2336/2706?show=full
[85] Hoffman A, Honigberg M. Glycated
hemoglobin as an integrator of
cardiovascular risk. İn individuals
without diabetes: Lessons from recent
epidemiologic studies. Current
Atherosclerosis Reports. 2022;24:435-
442. DOI: 10.1007/s11883-022-01024-8
[86] Pandey A, Vaduganathan M, Patel
KV, Ayers C, Ballantyne CM, Kosiborod
MN, et al. Biomarker-based risk
prediction of incident heart failure in
pre-diabetes and diabetes. JACC: Heart
Failure. 2021;9(3):215-223
[87] Ardissino M et al. Long-term
cardiovascular outcomes after orlistat
therapy in patients with obesity: A
nationwide, propensity-score matched
cohort study. European Heart JournalCardiovascular Pharmacotherapy. 2021;8
(2):179-186. DOI: 10.1093/ehjcvp/pvaa133
[88] Margulies KB, Hernandez AF,
Redfield MM, Givertz MM, Oliveira GH,
Cole R, et al. Effects of liraglutide on
clinical stability among patients with
advanced heart failure and reduced
ejection fraction: A randomized clinical
trial. Journal of the American Medical
Association. 2016;316(5):500-508
[89] Jorsal A, Kistorp C, et al. Effect of
liraglutide, a glucagon-like peptide-1
analogue, on left ventricular function in
stable chronic heart failure patients with
and without diabetes (LIVE)—A
multicentre, double-blind, randomised,
placebo-controlled trial. European
Journal of Heart. Failure. 2016;19(1):
69-77. DOI: 10.1002/EJHF.657
[90] Bozkurt B, Coats AJS, Tsutsui H,
Abdelhamid M, Adamopoulos S, Albert
N, et al. Universal definition and
classification of heart failure: A report of
the Heart Failure Society of America,
heart failure Association of the European
Society of cardiology, Japanese heart
failure society and writing Committee of
the Universal Definition of heart failure.
Journal of Cardiac Failure. 2021;27(4):
387-413
[91] McDonagh TA, Metra M, Adamo M,
Gardner RS, Baumbach A, Böhm M, et
al. ESC guidelines for the diagnosis and
treatment of acute and chronic heart
failure: Developed by the task force for
the diagnosis and treatment of acute and
chronic heart failure of the European
Society of Cardiology (ESC) with the
special contribution of the heart failure
association (HFA) of the ESC. European
Heart Journal. 2021;2:hea368
[92] Owan TE, Hodge DO, Herges RM,
Jacobsen SJ, Roger VL, Redfield MM.
Trends in prevalence and outcome of
heart failure with preserved ejection
fraction. The New England Journal of
Medicine. 2006;355(3):251-259
[93] Oktay AA, Rich JD, Shah SJ. The
emerging epidemic of heart failure with
preserved ejectionfraction.Current Heart
Failure Reports. 2013;10(4):401-410
[94] Ponikowski P, Voors AA, Anker SD,
Bueno H, Cleland JGF, Coats AJS, et al.
2016 ESC guidelines for the diagnosis
and treatment of acute and chronic heart
failure: The task force for the diagnosis
and treatment of acute and chronic heart
failure of the European Society of
Cardiology (ESC) developed with the
special contribution of the Heart Failure
Association (HFA) of the ESC. European
Heart Journal. 2016;37(27):2129-2200
[95] Meta-analysis Global Group in
Chronic Heart F. The survival of patients
25
Novel Pathogenesis and Treatments for Cardiovascular Disease
197
https://t.me/medicina_free
with heart failure with preserved or
reduced left ventricular ejection fraction:
An individual patient data meta-analysis.
European Heart Journal. 2012;33(14):
1750-1757
[96] Yancy Clyde W, Jessup M, Bozkurt
B, Butler J, Casey Donald E, Drazner
Mark H, et al. 2013 ACCF/AHA
guideline for the Management of Heart
Failure: Executive summary. Circulation.
2013;128(16):1810-1852
[97] Simmonds SJ, Cuijpers I, Heymans S,
Jones EAV. Cellular and molecular
differences between HFpEF and HFrEF:
A step ahead in an improved
pathological understanding. Cell.
2020;9:1
[98] Ho JE, Lyass A, Lee DS, Vasan RS,
Kannel WB, Larson MG, et al. Predictors
of new-onset heart failure: Differences in
preserved versus reduced ejection
fraction. Circulation. Heart Failure.
2013;6(2):279-286
[99] Type 2 Diabetes Mellitus and Heart
Failure. A scientific statement from the
American Heart Association and the
Heart Failure Society of America. © 2019
by the American Heart Association, Inc.,
and the Heart Failure Society of
America. Circulation. 2019;140:e294e324. DOI: 10.1161/
CIR.0000000000000691. Available
from: https://www.ahajournals.org/
journal/circ
[100] Shimizu I, Minamino T, Toko H, et
al. Excessive cardiac insulin signaling
exacerbates systolic dysfunction induced
by pressure overload in rodents. The
Journal of Clinical Investigation. 2010;
120(5):1506-1514. DOI: 10.1172/
JCI40096
[101] Iribarren C, Karter AJ, Go AS, et al.
Glycemic control and heart failure
among adult patients with diabetes.
Circulation. 2001;103:2668-2673. DOI:
10.1161/01.CIR.103.22.2668
[102] Nirengi S, Peres Valgas da Silva C,
Stanford KI. Disruption of energy
utilization in diabetic cardiomyopathy; a
mini review. Current Opinion in
Pharmacology. 2020;54:82-90
[103] Jia G, Hill MA, Sowers JR. Diabetic
cardiomyopathy: An update of
mechanisms contributing to this clinical
entity. Circulation Research. 2018;122
(4):624-638
[104] Jang SY, Jang J, Yang DH, Cho HJ,
Lim S, Jeon ES, et al. Impact of insulin
therapy on the mortality of acute heart
failure patients with diabetes mellitus.
Cardiovascular Diabetology. 2021;20(1):
180
[105] Levelt E, Rodgers CT, Clarke WT,
et al. Cardiac energetics, oxygenation,
and perfusion during increased workload
in patients with type 2 diabetes mellitus.
European Heart Journal. 2016;37:3461-
3469. DOI: 10.1093/eurheartj/ehv442
[106] Zaveri MP, Perry JC, Schuetz TM,
Memon MD, Faiz S, Cancarevic I.
Diabetic cardiomyopathy as a clinical
entity: Is it a myth? Cureus. 2020;12(10):
e11100
[107] Glass CK, Olefsky JM.
Inflammation and lipid signaling in the
etiology of insulin resistance. Cell
Metabolism. 2012;15:635-645. DOI:
10.1016/j.cmet. 2012.04.001
[108] Bonapace S, Valbusa F, Bertolini L,
et al. Early impairment in left ventricular
longitudinal systolic function is
associated with an increased risk of
incident atrial fibrillation in patients
with type 2 diabetes. Journal of Diabetes
and its Complications. 2017;31:413-418.
DOI: 10.1016/j.jdiacomp. 2016.10.032
26
Diabetes
198
https://t.me/medicina_free
DOI:
Mellitus Type 2, Prediabetes, and Chronic Heart Failure
http://dx.doi.org/10.5772/.106391
[109] Zheng H, Zhu H, Liu X, Huang X,
Huang A, Huang Y. Mitophagy in
diabetic cardiomyopathy: Roles and
mechanisms. Frontiers in Cell and
Developmental Biology. 2021;9:2675
[110] Shah MS, Brownlee M. Molecular
and cellular mechanisms of
cardiovascular disorders in diabetes.
Circulation Research. 2016;118:1808-
1829. DOI: 10.1161/
CIRCRESAHA.116.306923
[111] Bedi KC Jr, Snyder NW,
Brandimarto J, et al. Evidence for
intramyocardial disruption of lipid
metabolism and increased myocardial
ketone utilization in advanced human
heart failure. Circulation. 2016;133:706-
716. DOI: 10.1161/
CIRCULATIONAHA.115.017545
[112] Campbell P, Krim S, Ventura H.
The bi-directional impact of two chronic
illnesses: Heart failure and diabetes—A
review of the epidemiology and
outcomes. Cardiac Failure Review. 2015;
1(1):8-10. DOI: 10.15420/
cfr.2015.01.01.8
[113] Nielson С, Lange T. Blood glucose
and heart failure in nondiabetic patients.
Diabetes Care. 2005;28:3607-3611. DOI:
10.2337/diacare.28.3.607
[116] Cheng JM, Akkerhuis KM, Battes
LC, van Vark LC, Hillege HL, Paulus WJ,
et al. Biomarkers of heart failure with
normal ejection fraction: A systematic
review. European Journal of Heart
Failure. 2013;15(12):1350-1362
[117] Seferovic JP, Tesic M, Seferovic PM,
Lalic K, Jotic A, Biering-Sørensen T, et
al. Increased left ventricular mass index
is present in patients with type 2 diabetes
without ischemic heart disease. Scientific
Reports. 2018;8(1):926
[118] Lang RM, Badano LP, Mor-Avi V,
Afilalo J, Armstrong A, Ernande L, et al.
Recommendations for cardiac chamber
quantification by echocardiography in
adults: An update from the American
Society of Echocardiography and the
European Association of Cardiovascular
Imaging. European Heart Journal
Cardiovascular Imaging. 2015;16(3):
233-270
[119] Pham I, Cosson E, Nguyen MT,
Banu I, Genevois I, Poignard P, et al.
Evidence for a specific diabetic
cardiomyopathy: An observational
retrospective echocardiographic study in
656 asymptomatic type 2 diabetic
patients. International Journal of
Endocrinology. 2015;2015:743503
[114] Cosentino F, Grant PJ, Aboyans V,
Bailey CJ, Ceriello A, Delgado V, et al.
2019 ESC guidelines on diabetes, prediabetes, and cardiovascular diseases
developed in collaboration with the
EASD. European Heart Journal. 2020;41
(2):255-323
[115] Azevedo PS, Polegato BF, Minicucci
MF, Paiva SAR, Zornoff LAM. Cardiac
remodeling: Concepts, clinical impact,
pathophysiological mechanisms and
pharmacologic treatment. Arquivos
Brasileiros de Cardiologia. 2016;106(1):
62-69
27
[120] Heidenreich PA, Bozkurt B, Aguilar
D, Allen LA, Byun JJ, Colvin MM, et al.
AHA/ACC/HFSA guideline for the
Management of Heart Failure: A report
of the American College of Cardiology/
American Heart Association Joint
Committee on Clinical Practice
Guidelines. Circulation. 2022;145:e895e1032. DOI: 10.1161/CIR.0000000
000001063
[121] Yang S, Chen H, Tan K, Cai F, Du Y,
Lv W, et al. Secreted frizzled-related
protein 2 and extracellular volume
fraction in patients with heart failure.
Novel Pathogenesis and Treatments for Cardiovascular Disease
199
https://t.me/medicina_free
Oxidative Medicine and Cellular
Longevity. 2020;2020:2563508
[122] Wu Y, Liu X, Zheng H, Zhu H, Mai
W, Huang X, et al. Multiple roles of
sFRP2 in cardiac development and
cardiovascular disease. International
Journal of Biological Sciences. 2020;16
(5):730-738
[123] Wu J, Zheng H, Liu X, Chen P,
Zhang Y, Luo J, et al. Prognostic value of
secreted frizzled-related protein 5 in
heart failure patients with and without
type 2 diabetes mellitus. Circulation.
Heart Failure. 2020;13(9):e007054
[124] Huang A, Huang Y. Role of Sfrps in
cardiovascular disease. Therapeutic
Advances in Chronic Disease. 2020;11:
2040622320901990
[125] Kristensen SL, Jhund PS, Lee MMY,
Køber L, Solomon SD, Granger CB, et al.
Prevalence of prediabetes and
undiagnosed diabetes in patients with
HFpEF and HFrEF and associated
clinical outcomes. Cardiovascular
Drugs and Therapy. 2017;31(5–6):
545-549
[126] 10. Cardiovascular disease and risk
management: Standards of medical care
in diabetes— 2021. Diabetes Care. 2021;
44(Supplement 1):S125-SS50
hypertension study). Primary Care
Diabetes. 2021;15(2):332-339
[129] Zhu H, Zheng H, Liu X, Mai W,
Huang Y. Clinical applications for outof-office blood pressure monitoring.
Therapeutic Advances in Chronic
Disease. 2020;11:2040622320901660
[130] Sharma A, Verma S, Bhatt D, et al.
Optimizing foundational therapies in
patients with HFrEF. JACC: Basic to
Translational Science. 2022;7(5):504-517.
DOI: 10.1016/j.jacbts.2021.10.018
[131] Yoon S, Eom GH. Heart failure with
preserved ejection fraction: Present
status and future directions.
Experimental & Molecular Medicine.
2019;51(12):1-9
[132] Anker SD, Butler J, Filippatos G,
Ferreira JP, Bocchi E, Böhm M, et al.
Empagliflozin in heart failure with a
preserved ejection fraction. The New
England Journal of Medicine. 2021;9:25
[133] Vermes E, Ducharme A, Bourassa
MG, Lessard M, White M, Tardif JC.
Enalapril reduces the incidence of
diabetes in patients with chronic heart
failure: Insight from the studies of left
ventricular dysfunction (SOLVD).
Circulation. 2003;107(9):1291-1296
[127] Papadopoulos DP, Makris TK.
Masked hypertension definition, impact,
outcomes: A critical review. Journal of
Clinical Hypertension (Greenwich,
Conn.). 2007;9(12):956-963
[128] Sabuncu T, Sonmez A, Eren MA,
Sahin I, Çorapçioğlu D, Üçler R, et al.
Characteristics of patients with
hypertension in a population with type 2
diabetes mellitus. Results from the
Turkish Nationwide survey of Glycemic
and other metabolic parameters of
patients with Diabetes Mellitus (TEMD
28
[134] Waddingham MT, Edgley AJ,
Tsuchimochi H, Kelly DJ, Shirai M,
Pearson JT. Contractile apparatus
dysfunction early in the pathophysiology
of diabetic cardiomyopathy. World
Journal of Diabetes. 2015;6:943-960.
DOI: 10.4239/wjd.v6.i7.943
[135] McMurray JJ, Packer M, Desai AS,
Gong J, Lefkowitz MP, Rizkala AR, et al.
Angiotensin-neprilysin inhibition versus
enalapril in heart failure. The New
England Journal of Medicine. 2014;
371(11):993-1004
Diabetes
200
https://t.me/medicina_free
DOI:
Mellitus Type 2, Prediabetes, and Chronic Heart Failure
http://dx.doi.org/10.5772/.106391
[136] Solomon SD, McMurray JJV, Anand
IS, Ge J, Lam CSP, Maggioni AP, et al.
Angiotensin-neprilysin inhibition in
heart failure with preserved ejection
fraction. The New England Journal of
Medicine. 2019;381(17):1609-1620
[137] Seferovic JP, Claggett B,
Seidelmann SB, Seely EW, Packer M,
Zile MR, et al. Effect of sacubitril/
valsartan versus enalapril on glycaemic
control in patients with heart failure and
diabetes: A post-hoc analysis from the
PARADIGM-HF trial. The Lancet
Diabetes Endocrinology. 2017;5(5):
333-340
[138] Zile MR, Claggett BL, Prescott MF,
McMurray JJ, Packer M, Rouleau JL, et
al. Prognostic implications of changes in
N-terminal pro-B-type natriuretic
peptide in patients with heart failure.
Journal of the American College of
Cardiology. 2016;68(22):2425-2436
[142] Pitt B, Anker SD, Böhm M.
Rationale and design of
mineralocorticoid receptor antagonist
tolerability study-heart failure (ARTSHF): A randomized study of finerenone
vs eplerenone in patients who have
worsening chronic heart failure with
diabetes and/or chronic kidney disease.
European Journal of Heart Failure. 2015;
17(2):224-232. DOI: 10.1002/ejhf.218
[143] Zannad F, Ferreira JP, Pocock SJ,
Anker SD, Butler J, Filippatos G, et al.
SGLT2 inhibitors in patients with heart
failure with reduced ejection fraction: A
meta-analysis of the EMPEROR-reduced
and DAPA-HF trials. The Lancet. 2020;
396(10254):819-829
[144] Ferrannini E, Mark M, Mayoux E.
CV protection in the EMPAREG
OUTCOME trial: A “thrifty substrate”
hypothesis. Diabetes Care. 2016;39:
1108-1114. DOI: 10.2337/dci16–0033
[139] Cunningham JW, Vaduganathan M,
Claggett BL, Zile MR, Anand IS, Packer
M, et al. Effects of sacubitril/valsartan on
N-terminal pro-B-type natriuretic
peptide in heart failure with preserved
ejection fraction. JACC: Heart Failure.
2020;8(5):372-381
[140] Chen M-D, Dong S-S, Cai N-Y, Fan
M-D, Gu S-P, Zheng J-J, et al. Efficacy
and safety of mineralocorticoid receptor
antagonists for patients with heart
failure and diabetes mellitus: A
systematic review and meta-analysis.
BMC Cardiovascular Disorders. 2016;
16:28
[141] Filippatos G, Anker SD, Böhm M,
Gheorghiade M, Køber L, Krum H, et al.
A randomized controlled study of
finerenone vs. eplerenone in patients
with worsening chronic heart failure and
diabetes mellitus and/or chronic kidney
disease. European Heart Journal. 2016;
37(27):2105-2114
[145] McMurray JJV, Solomon SD,
Inzucchi SE, Køber L, Kosiborod MN,
Martinez FA, et al. Dapagliflozin in
patients with heart failure and reduced
ejection fraction. The New England
Journal of Medicine. 2019;381(21):
1995-2008
[146] Butt JH, Docherty KF, Petrie MC,
Schou M, Kosiborod MN, O’Meara E, et
al. Efficacy and safety of dapagliflozin in
men and women with heart failure with
reduced ejection fraction: A prespecified
analysis of the dapagliflozin and
prevention of adverse outcomes in heart
failure trial. JAMA Cardiology. 2021;
6(6):678-689
[147] Packer M, Anker SD, Butler J,
Filippatos G, Pocock SJ, Carson P, et al.
Cardiovascular and renal outcomes with
empagliflozin in heart failure. The New
England Journal of Medicine. 2020;383:
1413-1424
29
Соседние файлы в папке Библиотека им академика М.И. Перельмана